Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 14Genitourinary 13Lymphoid 12Sarcoma 9CNS 9Plasma cell 8Breast 6Myeloid 5Thoracic 4Other hematologic neoplasm 4Gynecologic 4Tumor-Agnostic 3Head & Neck 3Other solid neoplasm 2NET 2Endocrine 2Other neoplasm 1Dermatologic 1

Conditions

Neuroendocrine Tumors 2Non functioning pancreatic endocrine tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 13Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 4Octreotide 3Lutetium-177 3Ipilimumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1pasireotide 1entrectinib 1copper dotatate CU-64 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × X-Rays × NET × Clear all
NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡